The study will aim to enroll ninety-four (94) patients/care partners. The time period for enrollment is dependent on the uptake of KESIMPTA in the real-world.~Data collected for the study will be obtained directly from the patient/care partner within the web-based database: De-identified data will be stored on a secure server and transferred for analysis. Responses from the patient and care partner surveys will be pooled for analysis of study endpoints.
This is a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.